Soon, in the ten For all you blind DM lovers, get ready to throw tomatoes at me. Unfortunately, the share is still overvalued in my eyes. Why? I'll take round numbers. Datamatrex had a profit of $ 9,500,000 in Q1 of which 9,000,000 came from sales of COVID tests. As mentioned by another member of the forum, it is reasonable to believe that they have another 2 quarters before putting a cross on this income. And again, no announcement of an extended contract for the sale of the tests. But that’s profit is about 3 cents of the share's value. What then remains? AI technology, revenue of about $ 500,000 in Q1, a 40% decrease from Q1 of 2020. No AI contract announcements, nothing nothing nothing. And the stock is still trading above 20. So the market believes their technology (I'm taking the COVID test sales value off) around $ 50,000,000 even though they have $ 500,000 in income. I am not saying that DM is worthless, but not $ 50,000,000 for a technology that is shunned by the market. This is my opinion, I wish you the best